Joanna Craven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joanna Craven has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Flohr
St John's Institute of Dermatology King's College London and Guy's & St Thomas' NHS Foundation Trust London UK
1 shared publication - Gideon Lack
Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine King's College London London UK
1 shared publication - Kirsty Logan
Department of Women and Children’s Health, King's College London, London, UK
1 shared publication - Matthew J. Ridd
University of Bristol
1 shared publication - Michael Richard Perkin
Population Health Research Institute St. George's University of London London UK
1 shared publication - Rosie Vincent
Population Health Sciences University of Bristol Bristol UK
1 shared publication
Latest Publications
- 7 December 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 82-93
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data
Background: Non‐IgE‐mediated Cow's Milk Allergy (CMA) has a prevalence of less than 1% in children. Guidelines developed to help non‐specialists diagnose CMA may lead to misattribution of normal symptoms and contribute to overdiagnosis of CMA. We sought to establish the frequency of symptoms during infancy associated with non‐IgE‐mediated CMA, using the international Milk Allergy in Primary Care (iMAP) guideline as representative of CMA guidelines more generally.Method: Secondary analysis of the Enquiring About Tolerance (EAT) randomized controlled trial (ISRCTN 14254740; 1303 exclusively breastfed 3‐month‐old healthy infants). Key outcomes were ≥2 iMAP symptoms associated with ‘mild‐moderate’ and ‘severe’ non‐IgE‐mediated CMA.Results: Whilst breastfeeding and parental atopy rates were higher than the general population, participants were otherwise similar to the population of England and Wales. Two or more non‐IgE CMA symptoms were reported by 25% families for mild‐moderate and 1.4% for severe symptoms each month between ages 3 and 12 months, peaking at 38% with ≥2 mild‐moderate and 4.3% ≥2 severe symptoms at three months, when participants were not directly consuming cow's milk. 74% of participants reported ≥2 mild‐moderate symptoms and 9% ≥2 severe symptoms in at least one month during this period. At six months there was no evidence of difference in the proportion of children with ≥2 symptoms between those consuming (29.5% mild‐moderate, 1.8% severe) and not consuming cow's milk (35.3% mild‐moderate, 2.2% severe). Mean monthly reporting of ≥2 symptoms was also no different between those with (15.8% mild‐moderate, 1.1% severe) or without eczema at baseline (16.7% mild‐moderate, 1.3% severe).Conclusions: Guideline‐defined symptoms of non‐IgE‐mediated CMA are very common in infants. Guidelines may promote milk allergy overdiagnosis by labelling normal infant symptoms as possible milk allergy.
- 7 December 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 82-93
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data
Background: Non‐IgE‐mediated Cow's Milk Allergy (CMA) has a prevalence of less than 1% in children. Guidelines developed to help non‐specialists diagnose CMA may lead to misattribution of normal symptoms and contribute to overdiagnosis of CMA. We sought to establish the frequency of symptoms during infancy associated with non‐IgE‐mediated CMA, using the international Milk Allergy in Primary Care (iMAP) guideline as representative of CMA guidelines more generally.Method: Secondary analysis of the Enquiring About Tolerance (EAT) randomized controlled trial (ISRCTN 14254740; 1303 exclusively breastfed 3‐month‐old healthy infants). Key outcomes were ≥2 iMAP symptoms associated with ‘mild‐moderate’ and ‘severe’ non‐IgE‐mediated CMA.Results: Whilst breastfeeding and parental atopy rates were higher than the general population, participants were otherwise similar to the population of England and Wales. Two or more non‐IgE CMA symptoms were reported by 25% families for mild‐moderate and 1.4% for severe symptoms each month between ages 3 and 12 months, peaking at 38% with ≥2 mild‐moderate and 4.3% ≥2 severe symptoms at three months, when participants were not directly consuming cow's milk. 74% of participants reported ≥2 mild‐moderate symptoms and 9% ≥2 severe symptoms in at least one month during this period. At six months there was no evidence of difference in the proportion of children with ≥2 symptoms between those consuming (29.5% mild‐moderate, 1.8% severe) and not consuming cow's milk (35.3% mild‐moderate, 2.2% severe). Mean monthly reporting of ≥2 symptoms was also no different between those with (15.8% mild‐moderate, 1.1% severe) or without eczema at baseline (16.7% mild‐moderate, 1.3% severe).Conclusions: Guideline‐defined symptoms of non‐IgE‐mediated CMA are very common in infants. Guidelines may promote milk allergy overdiagnosis by labelling normal infant symptoms as possible milk allergy.